Role of myelin proteolipoprotein expression in spinal ganglion glial satellite cells and spinal sensory neurons in pain control

Neuropathic pain is a chronic condition that significantly impacts patients’ quality of life, arising from lesions or diseases of the somatosensory nervous system. It manifests in various conditions, such as trigeminal neuralgia, painful polyneuropathies, multiple sclerosis, and central post-stroke pain, and is characterized by spontaneous or evoked sensations, including burning, tingling, or intense pressure. The underlying mechanisms involve ectopic activity in structures such as dorsal root ganglia (DRG), thalamus, or nerve terminals, along with maladaptive structural changes, central and peripheral sensitization, and interactions among neurons, glial, and immune cells.

Despite first-line pharmacological treatments like anticonvulsants and tricyclic antidepressants, many patients remain resistant, relying on second-line therapies like opioids or lidocaine patches, which carry significant side effects. Alternative strategies, including targeting Nav1.7 and TRPV1 channels, gene therapy, stem cells, or DRG stimulation, have shown potential. The DRG, housing the cell bodies of sensory neurons, plays a central role in transmitting sensory information and pain signals, supported by glial and immune cells. Recent studies identified the presence of myelin proteolipid protein (PLP) in the DRG, particularly in satellite glial cells (SGCs), suggesting its role in pain modulation.

PLP, primarily expressed in CNS myelin, also exists in peripheral myelin and other tissues, where it facilitates myelin compaction and axonal metabolic support. Dysregulation or absence of PLP has been linked to sensory disturbances, including hyperalgesia and mechanical allodynia. Emerging evidence highlights PLP’s influence on the EphrinB/EphB signaling pathway, central sensitization, and thermal hyperalgesia. Given the proximity of SGCs to neurons within the DRG and their regulatory role in neuronal activity and homeostasis, PLP may be a key modulator of pain.

This study aims to elucidate the role of PLP in SGCs within the DRG in pain modulation. Using a developmental approach with Cre/Lox to knock out PLP in SGCs and a CRISPR/Cas9 strategy to downregulate PLP expression in adult mice, we seek to clarify PLP’s involvement in pain regulation and its therapeutic potential in neuropathic pain.

#Pain #Dorsal root ganglia #PLP1 #CrisprCas9 #Cre/Lox

Role of myelin proteolipoprotein expression in spinal ganglion glial satellite cells and spinal sensory neurons in pain control

Neuropathic pain is a chronic condition that significantly impacts patients’ quality of life, arising from lesions or diseases of the somatosensory nervous system. It manifests in various conditions, such as trigeminal neuralgia, painful polyneuropathies, multiple sclerosis, and central post-stroke pain, and is characterized by spontaneous or evoked sensations, including burning, tingling, or intense pressure. The underlying mechanisms involve ectopic activity in structures such as dorsal root ganglia (DRG), thalamus, or nerve terminals, along with maladaptive structural changes, central and peripheral sensitization, and interactions among neurons, glial, and immune cells.

Despite first-line pharmacological treatments like anticonvulsants and tricyclic antidepressants, many patients remain resistant, relying on second-line therapies like opioids or lidocaine patches, which carry significant side effects. Alternative strategies, including targeting Nav1.7 and TRPV1 channels, gene therapy, stem cells, or DRG stimulation, have shown potential. The DRG, housing the cell bodies of sensory neurons, plays a central role in transmitting sensory information and pain signals, supported by glial and immune cells. Recent studies identified the presence of myelin proteolipid protein (PLP) in the DRG, particularly in satellite glial cells (SGCs), suggesting its role in pain modulation.

PLP, primarily expressed in CNS myelin, also exists in peripheral myelin and other tissues, where it facilitates myelin compaction and axonal metabolic support. Dysregulation or absence of PLP has been linked to sensory disturbances, including hyperalgesia and mechanical allodynia. Emerging evidence highlights PLP’s influence on the EphrinB/EphB signaling pathway, central sensitization, and thermal hyperalgesia. Given the proximity of SGCs to neurons within the DRG and their regulatory role in neuronal activity and homeostasis, PLP may be a key modulator of pain.

This study aims to elucidate the role of PLP in SGCs within the DRG in pain modulation. Using a developmental approach with Cre/Lox to knock out PLP in SGCs and a CRISPR/Cas9 strategy to downregulate PLP expression in adult mice, we seek to clarify PLP’s involvement in pain regulation and its therapeutic potential in neuropathic pain.

#Pain #Dorsal root ganglia #PLP1 #CrisprCas9 #Cre/Lox

internship supervisor

Dr. Mélina BEGOU